Affiliation:
1. Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey
Abstract
Introduction Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy. Case Report A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams. Management & Outcome The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy. Discussion Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.
Subject
Pharmacology (medical),Oncology
Reference17 articles.
1. Clark JW, Sanoff HK. Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach, https://www.uptodate.com/contents/systemic-therapy-for-nonoperable-metastatic-colorectal-cancer-selecting-the-initial-therapeutic-approach/ (accessed 26 December 2020).
2. K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
3. Cetuximab
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献